Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical Durvalumab for High-Risk Non-Muscle-Invasive Bladder Cancer
2018-002100-13Phase 2Completed
- Sponsor
- Hellenic Genito-Urinary Cancer Group
- Start
- Sep 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in bladder cancer, sponsored by Hellenic Genito-Urinary Cancer Group. Primary endpoint: Safety assessments. Started Sep 2018; status: completed.
02
Drugs
durvalumab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2018-002100-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002100-13.